SEC31A Antibody

Total Page:16

File Type:pdf, Size:1020Kb

SEC31A Antibody Efficient Professional Protein and Antibody Platforms SEC31A Antibody Basic information: Catalog No.: UMA21146 Source: Mouse Size: 50ul/100ul Clonality: Monoclonal 5D12C6 Concentration: 1mg/ml Isotype: Mouse IgG1 Purification: The antibody was purified by immunogen affinity chromatography. Useful Information: WB:1:500 - 1:2000 Applications: IHC:1:200 - 1:1000 ELISA:1:10000 Reactivity: Human Specificity: This antibody recognizes SEC31A protein. Purified recombinant fragment of human SEC31A (AA: 429-571) expressed Immunogen: in E. Coli. The protein encoded by this gene shares similarity with the yeast Sec31 protein, and is a component of the outer layer of the coat protein complex II (COPII). The encoded protein is involved in vesicle budding from the endo- plasmic reticulum (ER) and contains multiple WD repeats near the N-terminus and a proline-rich region in the C-terminal half. It associates Description: with the protein encoded by the SEC13 homolog, nuclear pore and COPII coat complex component (SEC13), and is required for ER-Golgi transport. Monoubiquitylation of this protein by CUL3-KLHL12 was found to regulate the size of COPII coats to accommodate unusually shaped cargo. Alternative splicing results in multiple transcript variants encoding different isoforms. Uniprot: O94979 BiowMW: 133kDa Buffer: Purified antibody in PBS with 0.05% sodium azide Storage: Store at 4°C short term and -20°C long term. Avoid freeze-thaw cycles. Note: For research use only, not for use in diagnostic procedure. Data: Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng) Gene Universal Technology Co. Ltd www.universalbiol.com Tel: 0550-3121009 E-mail: [email protected] Efficient Professional Protein and Antibody Platforms Figure 2:Western blot analysis using SEC31A mAb against human SEC31A (AA: 429-571) recombi- nant protein. (Expected MW is 41.8 kDa) Figure 3:Western blot analysis using SEC31A mAb against HEK293 (1) and SEC31A (AA: 429-571)-hIgGFc transfected HEK293 (2) cell ly- sate. Figure 4:Immunohistochemical analysis of paraf- fin-embedded ovarian cancer tissues using SEC31A mouse mAb with DAB staining. Gene Universal Technology Co. Ltd www.universalbiol.com Tel: 0550-3121009 E-mail: [email protected] .
Recommended publications
  • Old Data and Friends Improve with Age: Advancements with the Updated Tools of Genenetwork
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.24.445383; this version posted May 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Old data and friends improve with age: Advancements with the updated tools of GeneNetwork Alisha Chunduri1, David G. Ashbrook2 1Department of Biotechnology, Chaitanya Bharathi Institute of Technology, Hyderabad 500075, India 2Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA Abstract Understanding gene-by-environment interactions is important across biology, particularly behaviour. Families of isogenic strains are excellently placed, as the same genome can be tested in multiple environments. The BXD’s recent expansion to 140 strains makes them the largest family of murine isogenic genomes, and therefore give great power to detect QTL. Indefinite reproducible genometypes can be leveraged; old data can be reanalysed with emerging tools to produce novel biological insights. To highlight the importance of reanalyses, we obtained drug- and behavioural-phenotypes from Philip et al. 2010, and reanalysed their data with new genotypes from sequencing, and new models (GEMMA and R/qtl2). We discover QTL on chromosomes 3, 5, 9, 11, and 14, not found in the original study. We narrowed down the candidate genes based on their ability to alter gene expression and/or protein function, using cis-eQTL analysis, and variants predicted to be deleterious. Co-expression analysis (‘gene friends’) and human PheWAS were used to further narrow candidates.
    [Show full text]
  • Leukaemia Section
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Short Communication t(4;9)(q21.22;p24) SEC31A/JAK2 Julie Sanford Biggerstaff Idaho Cytogenetics Diagnostic Laboratory, Boise, ID 83706, USA; [email protected] Published in Atlas Database: April 2017 Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0409q21p24ID1682.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68905/04-2017-t0409q21p24ID1682.pdf DOI: 10.4267/2042/68905 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2018 Atlas of Genetics and Cytogenetics in Oncology and Haematology Abstract Cytogenetics Review on t(4;9)(q21.22;p24) SEC31A/JAK2, with data on clinics, and the genes involved. Cytogenetics morphological KEYWORDS JAK2 breakapart (commonly available). Chromosome 4; chromosome 9; translocation; SEC31A; JAK2; Hodgkin Lymphoma Genes involved and Clinics and pathology proteins SEC31A (SEC31 homolog A, COPII Disease coat complex component) Hodgkin Lymphoma Location Phenotype/cell stem origin 4q21.22 Hodgkin and Reed-Sternberg cells, which derive DNA/RNA from pre-apoptotic crippled germinal center (GC) B- gene is 72,606 bp with 25 exons; transcribed from cells, are positive for CD30, CD15, CD40 and the - strand; coding region is 62,863 bp with 24 IRF4/MUM1 exons Epidemiology Protein Hodgkin lymphoma itself is common, but this 1166 amnio acids. Protein transport protein SEC31A particular translocation may be rare within the is ubiquitously expressed and forms part of the coat disorder. However, it is not often assayed for; found protein complex II (COPII) which is comprised of at in 2/131 cHL cases examined: a M/31 with nodular least four other proteins in addition to SEC31A this sclerosis cHL, alive 60 mths after diagnosis; and a complex is involved in formation of transport M/83 with lymphocyte-depleted cHL who died at vesicles from the ER to Golgi.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • Cytogenetically Complex SEC31A-ALK Fusions Are Recurrent
    Letters to the Editor A 1.5 30 Takashi Uchiyama from the Deptartment of Hematology/Oncology, ETV6-ABL1 WBC Kyoto University Hospital, Japan for following the patient in Japan, Tony Deblasio for collecting and storing the samples, and Emily 1.0 20 Dolezal for generating the database that facilitated our analysis. ETV6-ABL1 WBC (fold-change in (x109/ L) Correspondence: Stephen D. Nimer, MD, Memorial Sloan transcript level) μ Kettering Cancer Center, 1275 York Avenue, New York, NY 0.5 10 10065, USA. Phone: international +1.646.8883040. Fax: international +1.646.4220246. E-mail: [email protected] Key words: myeloproliferative, neoplasm, imatinib, molecular 0.0 0 response. 2.7.06 5.9.06 1.25.05 9.13.05 5.20.08 4.28.09 Citation: Perna F, Abdel-Wahab O, Levine RL, Jhanwar SC, 08.09.05 11.01.05 Imada K, and Nimer SD. ETV6-ABL1-positive “chronic myeloid 1.5 leukemia”: clinical and molecular response to tyrosine kinase inhibi- B c-myc tion with imatinib. Haematologica 2011; 96(02):342-343. BCL-XL doi:10.3324/haematol.2010.036673 ld1 1.0 NuP98 Fold-change (relative to References HPRT1) 0.5 1. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer. 1997;20(3): 0.0 299-304. 2. Barbouti A, Ahlgren T, Johansson B, Hoglund M, Lassen C, 2.7.06 5.9.06 1.25.05 9.13.05 Turesson I, et al. Clinical and genetic studies of ETV6/ABL1-posi- 08.09.05 11.01.05 tive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    [Show full text]
  • 1 the TRAPP Complex Mediates Secretion Arrest Induced by Stress Granule Assembly Francesca Zappa1, Cathal Wilson1, Giusepp
    bioRxiv preprint doi: https://doi.org/10.1101/528380; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The TRAPP complex mediates secretion arrest induced by stress granule assembly Francesca Zappa1, Cathal Wilson1, Giuseppe Di Tullio1, Michele Santoro1, Piero Pucci2, Maria Monti2, Davide D’Amico1, Sandra Pisonero Vaquero1, Rossella De Cegli1, Alessia Romano1, Moin A. Saleem3, Elena Polishchuk1, Mario Failli1, Laura Giaquinto1, Maria Antonietta De Matteis1, 2 1 Telethon Institute of Genetics and Medicine, Pozzuoli (Naples), Italy 2 Federico II University, Naples, Italy 3 Bristol Renal, Bristol Medical School, University of Bristol, UK Correspondence to: [email protected], [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/528380; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The TRAnsport-Protein-Particle (TRAPP) complex controls multiple membrane trafficking steps and is thus strategically positioned to mediate cell adaptation to diverse environmental conditions, including acute stress. We have identified TRAPP as a key component of a branch of the integrated stress response that impinges on the early secretory pathway. TRAPP associates with and drives the recruitment of the COPII coat to stress granules (SGs) leading to vesiculation of the Golgi complex and an arrest of ER export.
    [Show full text]
  • Identification of Prognosis Biomarkers of Prostatic Cancer in a Cohort Of
    Current Problems in Cancer 43 (2019) 100503 Contents lists available at ScienceDirect Current Problems in Cancer journal homepage: www.elsevier.com/locate/cpcancer Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA ∗ Zhiqiang Chen , Haiyi Hu Department of Urology, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China a b s t r a c t Objective: Prostatic cancer (PCa) is the first common cancer in male, and the prognostic variables are ben- eficial for clinical trial design and treatment strategies for PCa. This study was performed to identify more potential biomarkers for the prognosis of patients with PCa. Methods and results: The transcriptome data and survival information of a cohort including 498 subjects with PCa were downloaded from TCGA . A total of 4293 differentially expressed genes (DEGs), including 1362 prognosis-related DEGs, were identified in PCa tissues compared with normal tissues. Upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7 and SRSF8 ), and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1 and UBE2E1 ), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients. Several downregulated Golgi-ER traffic mediators (such as SEC31A, TMED2, and TMED10 ) were identified as positive prognostic biomarkers of PCa, as the high expression of them correlated with good overall survival of PCa patients. Conclusions: These genes were of great interests in prognosis of PCa, and some of them may be constructive for the augmentation of clinical trial design and treatment strategies for PCa.
    [Show full text]
  • Gene- and Tissue-Level Interactions in Normal Gastrointestinal Development and Hirschsprung Disease
    Gene- and tissue-level interactions in normal gastrointestinal development and Hirschsprung disease Sumantra Chatterjeea,b,1, Priyanka Nandakumara,1, Dallas R. Auera,b, Stacey B. Gabrielc, and Aravinda Chakravartia,b,2 aCenter for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205; bCenter for Human Genetics and Genomics, New York University School of Medicine, New York, NY 10016; and cGenomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142 Contributed by Aravinda Chakravarti, November 1, 2019 (sent for review May 21, 2019; reviewed by William J. Pavan and Tatjana Sauka-Spengler) The development of the gut from endodermal tissue to an organ between the longitudinal and circular muscles, and the sub- with multiple distinct structures and functions occurs over a mucosal (Meissner’s) plexus, between the circular muscle and prolonged time during embryonic days E10.5–E14.5 in the mouse. the submucosal layer. The myenteric and submucoal plexuses During this process, one major event is innervation of the gut by provide motor innervation to both muscular layers of the gut, enteric neural crest cells (ENCCs) to establish the enteric nervous and secretomotor innervation of the mucosa nearest the lumen system (ENS). To understand the molecular processes underpinning of the gut, respectively (6). gut and ENS development, we generated RNA-sequencing profiles The many stages of gut development require numerous initiat- from wild-type mouse guts at E10.5, E12.5, and E14.5 from both ing signaling events activating transcription factors (TFs) targeting sexes. We also generated these profiles from homozygous Ret null diverse genes and pathways varying across development (7, 8).
    [Show full text]
  • Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney
    Original Investigation Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics Esther Liu,1 Behram Radmanesh,1 Byungha H. Chung,2 Michael D. Donnan,1 Dan Yi,1 Amal Dadi,1 Kelly D. Smith,3 Jonathan Himmelfarb,2 Mingyao Li,4 Benjamin S. Freedman,2,3 and Jennie Lin 1,5 Abstract Background DNA variants in APOL1 associate with kidney disease, but the pathophysiologic mechanisms remain incompletely understood. Model organisms lack the APOL1 gene, limiting the degree to which disease states can be recapitulated. Here we present single-cell RNA sequencing (scRNA-seq) of genome-edited human kidney organoids as a platform for profiling effects of APOL1 risk variants in diverse nephron cell types. Methods We performed footprint-free CRISPR-Cas9 genome editing of human induced pluripotent stem cells (iPSCs) to knock in APOL1 high-risk G1 variants at the native genomic locus. iPSCs were differentiated into kidney organoids, treated with vehicle, IFN-g, or the combination of IFN-g and tunicamycin, and analyzed with scRNA-seq to profile cell-specific changes in differential gene expression patterns, compared with isogenic G0 controls. Results Both G0 and G1 iPSCs differentiated into kidney organoids containing nephron-like structures with glomerular epithelial cells, proximal tubules, distal tubules, and endothelial cells. Organoids expressed detectable APOL1 only after exposure to IFN-g. scRNA-seq revealed cell type–specific differences in G1 organoid response to APOL1 induction. Additional stress of tunicamycin exposure led to increased glomerular epithelial cell dedifferentiation in G1 organoids. Conclusions Single-cell transcriptomic profiling of human genome-edited kidney organoids expressing APOL1 risk variants provides a novel platform for studying the pathophysiology of APOL1-mediated kidney disease.
    [Show full text]
  • Transposable Element Expression at Unique Loci in Single Cells with CELLO-Seq
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.02.322073; this version posted October 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transposable element expression at unique loci in single cells with CELLO-seq Rebecca V Berrens*1, Andrian Yang #2, Christopher E Laumer #2, Aaron TL Lun 1,4, Florian Bieberich 1,5, Cheuk-Ting Law 1,6, Guocheng Lan 1,7, Maria Imaz 3,8, Daniel Gaffney 3,9, John C Marioni *1,2,3 1 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. 2 European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, CB10 1SD Hinxton, Cambridge, UK. 3 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK. # = equal contribution * = corresponding authors For correspondence = [email protected], [email protected] Current addresses: 4 Genentech, 1 DNA Way, South San Francisco, CA 94080, United States 5 ETH Zürich, D-BSSE, Mattenstrasse 26, 4058 Basel, Switzerland 6 Department of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong 7 School of Biomedical Sciences,Stem Cell and Regenerative Consortium, Centre for PanorOmic Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong 8 Division of Cardiovascular Medicine, University of Cambridge, United Kingdom 9 Genomics Plc, King Charles House, Park End St, Oxford OX1 1JD 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.02.322073; this version posted October 2, 2020.
    [Show full text]
  • Downloaded Per Proteome Cohort Via the Web- Site Links of Table 1, Also Providing Information on the Deposited Spectral Datasets
    www.nature.com/scientificreports OPEN Assessment of a complete and classifed platelet proteome from genome‑wide transcripts of human platelets and megakaryocytes covering platelet functions Jingnan Huang1,2*, Frauke Swieringa1,2,9, Fiorella A. Solari2,9, Isabella Provenzale1, Luigi Grassi3, Ilaria De Simone1, Constance C. F. M. J. Baaten1,4, Rachel Cavill5, Albert Sickmann2,6,7,9, Mattia Frontini3,8,9 & Johan W. M. Heemskerk1,9* Novel platelet and megakaryocyte transcriptome analysis allows prediction of the full or theoretical proteome of a representative human platelet. Here, we integrated the established platelet proteomes from six cohorts of healthy subjects, encompassing 5.2 k proteins, with two novel genome‑wide transcriptomes (57.8 k mRNAs). For 14.8 k protein‑coding transcripts, we assigned the proteins to 21 UniProt‑based classes, based on their preferential intracellular localization and presumed function. This classifed transcriptome‑proteome profle of platelets revealed: (i) Absence of 37.2 k genome‑ wide transcripts. (ii) High quantitative similarity of platelet and megakaryocyte transcriptomes (R = 0.75) for 14.8 k protein‑coding genes, but not for 3.8 k RNA genes or 1.9 k pseudogenes (R = 0.43–0.54), suggesting redistribution of mRNAs upon platelet shedding from megakaryocytes. (iii) Copy numbers of 3.5 k proteins that were restricted in size by the corresponding transcript levels (iv) Near complete coverage of identifed proteins in the relevant transcriptome (log2fpkm > 0.20) except for plasma‑derived secretory proteins, pointing to adhesion and uptake of such proteins. (v) Underrepresentation in the identifed proteome of nuclear‑related, membrane and signaling proteins, as well proteins with low‑level transcripts.
    [Show full text]
  • Regulation of Sec16 Levels and Dynamics Links Proliferation And
    ß 2015. Published by The Company of Biologists Ltd | Journal of Cell Science (2015) 128, 670–682 doi:10.1242/jcs.157115 RESEARCH ARTICLE Regulation of Sec16 levels and dynamics links proliferation and secretion Kerstin D. Tillmann1,2, Veronika Reiterer1, Francesco Baschieri1,2, Julia Hoffmann3, Valentina Millarte1,2, Mark A. Hauser1, Arnon Mazza4, Nir Atias4, Daniel F. Legler1, Roded Sharan4, Matthias Weiss3,* and Hesso Farhan1,2,* ABSTRACT proteins to downstream sites of the secretory pathway (Budnik and Stephens,2009; Lee et al., 2004; Zanetti et al., 2012). Sec16A We currently lack a broader mechanistic understanding of the (hereafter called Sec16) plays an important role in ERES integration of the early secretory pathway with other homeostatic homeostasis as it interacts with several COPII components and processes such as cell growth. Here, we explore the possibility regulates their function (Bhattacharyya and Glick, 2007; that Sec16A, a major constituent of endoplasmic reticulum exit Connerly et al., 2005; Farhan et al., 2008; Ivan et al., 2008; sites (ERES), acts as an integrator of growth factor signaling. Supek et al., 2002; Watson et al., 2006; Espenshade et al., 1995; Surprisingly, we find that Sec16A is a short-lived protein that is Gimeno et al., 1996; Whittle and Schwartz, 2010; Kung et al., regulated by growth factors in a manner dependent on Egr family 2012). Various post-translational modifications, such as transcription factors. We hypothesize that Sec16A acts as a central phosphorylation (Farhan et al., 2010; Koreishi et al., 2013; node in a coherent feed-forward loop that detects persistent growth Lord et al., 2011; Sharpe et al., 2011), ubiquitylation (Jin et al., factor stimuli to increase ERES number.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]